Clinical Trials Directory

Trials / Unknown

UnknownNCT05897151

Continuous Spinal Anesthesia Versus General Anesthesia in Sepsis

Comparative Study Between Continuous Spinal Anesthesia Versus General Anesthesia in Patients With Sepsis

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
110 (estimated)
Sponsor
Mahmoud Rashad Ahmed · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

The anesthetic efficacy and safety of continuous spinal anesthesia and comparing it with general anesthesia technique in sepsis diagnosed patient.

Detailed description

Hemodynamic instability due to high block largely limits the use of conventional dose spinal anesthesia in high-risk septic patients. Hypotension is more common, and also more hazardous, in septic patients, as they may have decreased physiological reserve and compromised blood supply to various vital organs. A smaller dose of local anesthetic reduces the severity and incidence of hypotension during spinal anesthesia.

Conditions

Interventions

TypeNameDescription
DRUGContinuous spinal anesthesiaPreservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics. Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure \< 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics.
DRUGGeneral anesthesiaAfter establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.

Timeline

Start date
2023-06-10
Primary completion
2023-11-30
Completion
2023-11-30
First posted
2023-06-09
Last updated
2023-06-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05897151. Inclusion in this directory is not an endorsement.